REGENXBIO/$RGNX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About REGENXBIO

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Ticker

$RGNX
Primary listing

Industry

Biotechnology

Employees

353

ISIN

US75901B1070

REGENXBIO Metrics

BasicAdvanced
$438M
-
-$3.10
1.11
-

What the Analysts think about REGENXBIO

Analyst ratings (Buy, Hold, Sell) for REGENXBIO stock.

Bulls say / Bears say

REGENXBIO's RGX-121, targeting Hunter syndrome, is under FDA review with a PDUFA date set for November 9, 2025, potentially positioning it as a new standard of care. (Seeking Alpha)
The company reported new positive functional data from the Phase I/II AFFINITY DUCHENNE® trial of RGX-202, demonstrating consistent evidence of positively changing disease trajectory for Duchenne. (PRNewsWire)
REGENXBIO announced a strategic royalty monetization agreement for up to $250 million, securing $150 million at closing, which extends its cash runway into early 2027. (PRNewsWire)
In Q1 2025, REGENXBIO reported earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.41, representing an earnings surprise of -70.73%. (Nasdaq)
The company exhibits a negative EPS of -$3.09 and a concerning return on equity of -47.44%, highlighting financial challenges typical of clinical-stage biotech firms. (DirectorsTalk Interviews)
REGENXBIO's stock price has exhibited significant volatility, dropping from approximately $28.00 at the beginning of the year to around $23.00 by September 30, 2024, reflecting a decline of about 17.86%. (DCF.fm)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

REGENXBIO Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

REGENXBIO Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $RGNX

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs